Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of HGH Fragment 176-191 and Liraglutide — mechanism, side effects, legal status, and pricing.
HGH Fragment 176-191 is a synthetic 16-residue disulfide-cyclized peptide corresponding to the C-terminal region (residues 176–191) of human growth hormone. It is classified as a lipolytic/GH-fragment peptide, not a full growth hormone. The compound is prohibited at all times under WADA Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Not FDA-approved for any indication; clinical development of the related analogue AOD9604 was discontinued in 2007 after a pivotal Phase IIb obesity trial failed its primary efficacy endpoint.
Liraglutide is an FDA-approved GLP-1 receptor agonist marketed as Victoza (type 2 diabetes, approved 2010) and Saxenda (chronic weight management, approved 2014). It was the first GLP-1 analog approved for obesity and carries an FDA boxed warning for the risk of thyroid C-cell tumors. Pediatric indications include type 2 diabetes in patients ≥10 years (Victoza) and obesity in patients ≥12 years with BMI ≥95th percentile (Saxenda).
HGH Fragment 176-191
Liraglutide
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
HGH Fragment 176-191
No pricing data yet.
Check HGH Fragment 176-191 prices →Liraglutide
1 vendor lists this, but none clear the trust bar (score ≥70) yet.
Check Liraglutide prices →COA corpus from Disclosed Labs — independently tested batches only.
HGH Fragment 176-191
1
COAs
99.2%
Avg purity
1
Labs
Liraglutide
No COA data yet.
Submit testing data →No human data were found for the native peptide (CAS 66004-57-7, Phe176) itself. All identified human clinical work was conducted on AOD9604, a distinct N-terminal Tyr-substituted analogue: six sponsor-run, randomized, double-blind, placebo-controlled trials (Phase I–IIb, 2001–2006, ~900 total subjects, including a ~502-subject 24-week Phase IIb obesity trial) assessed safety and later weight-loss efficacy. Reported: good tolerability, no serious adverse events, no IGF-1 elevation—but the pivotal Phase IIb trial did not meet its primary weight-loss endpoint versus placebo and Metabolic Pharmaceuticals discontinued development in 2007. In obese Zucker rats, oral AOD9604 (500 µg/kg/day × 19 days) reduced body-weight gain by >50% and increased adipose lipolytic activity without impairing insulin sensitivity. In obese and lean mice, both hGH and AOD9604 reduced weight gain and increased fat oxidation and plasma glycerol; unlike hGH, AOD9604 caused no hyperglycemia and did not compete for the hGH receptor. In β3-AR knockout mice, chronic lipolytic/weight effects were lost while acute energy-expenditure increases persisted. Intra-articular AOD9604 combined with hyaluronic acid outperformed either agent alone in a rabbit collagenase-induced knee osteoarthritis model.
Key references
The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM 2015; PMID 26132939) demonstrated ~8% body-weight loss at 3.0 mg daily over 56 weeks, and the SCALE Diabetes trial (Davies et al., JAMA 2015; PMID 26284720) showed 6.0% weight loss in adults with type 2 diabetes. The LEADER cardiovascular outcomes trial (Marso et al., NEJM 2016; PMID 27295427) demonstrated a 13% relative reduction in major adverse cardiovascular events in type 2 diabetes with established CVD or high CV risk. A pediatric Phase 3 trial (Kelly et al., NEJM 2020; PMID 32233338) supported Saxenda's FDA approval for adolescents ≥12 years with obesity. While less effective than newer GLP-1 agonists for weight loss, liraglutide has the longest track record and most extensive real-world safety data. The daily dosing requirement is its main disadvantage versus weekly semaglutide.
HGH Fragment 176-191 and Liraglutide are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs